Champions Oncology vs Alpha Teknova
Champions Oncology is the larger business, with $59.4m of revenue in fiscal 2026 against $40.5m for Alpha Teknova (1.5 times as much). Alpha Teknova grew faster (7.4% against 4.4%). Champions Oncology kept more of each dollar of sales as profit: a net margin of -2.0% against -42.6%.
| Latest fiscal year | Champions OncologyCSBR, 2026 | Alpha TeknovaTKNO, 2025 |
|---|---|---|
| Revenue | $59.4m | $40.5m |
| Revenue growth | 4.4% | 7.4% |
| Net income | −$1.2m | −$17.3m |
| Operating margin | -1.9% | — |
| Net margin | -2.0% | -42.6% |
| Return on equity | -30.5% | -22.8% |
| Free cash flow | −$5.0m | −$9.8m |
| Cash | $4.9m | $5.9m |
| Total debt | $0 | $13.2m |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 214 | 158 |
| Market value | $66.9m | $376m |
| Price vs our value range | — | — |
| Moat score | 63 (Moderate) | 13 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 2 buys, 0 sales |